- 1 Type of the Paper (Article)
- 2 Molecular Insights of β-Lactamics Resistance Klebsiella pneumoniae Isolates with
- **Focus on Multidrug Resistance and Virulence from Colonization Samples**
- 5 Lavouisier F.B. Nogueira", Marília S. Maia", Marco A.F. Clementino", Ila F.N. Lima, Jorge L.N.
- 6 Rodrigues, Luciana V.C. Fragoso, Glairta S. Costa, Jose Q.S. Filho, Alexandre Havt, Deiziane
- 7 V.S. Costa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman, José K. Sousa* and
- 8 Aldo A.M. Lima*

4

23

- 9 # These authors contributed equally to this work.
- 10 * Corresponding authors.
- 11 Abstract: Klebsiella pneumoniae is associated with high resistance to antimicrobials and 12 is common in isolates from colonization and nosocomial infections. This study aims to 13 develop assays to detect resistance genes belonging to the bla family and investigate 14 metabolic pathways in resistant isolates of *K. pneumoniae*. The genes of the subfamilies 15 included were: blaSHV, blaTEM, blaNDM, blaKPC, blaGES, blaCTX-M and relevant 16 variants of the blaOXA subfamily. Mass spectrometry data were acquired on the 17 Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system. Isolates 18 from 122 K. pneumoniae samples were collected from 04/23/2019 to 05/29/2021. A high 19 prevalence of resistance to penicillins, cephalosporins and carbapenems was found 20 among the isolates. The identified genotypic profile showed a high prevalence of genes 21 belonging to Ambler's classes of beta-lactamases A, B and D. In the metabolomic study, 22 the N-fructosyl isoleucine metabolite was identified increased in multidrug-resistant

(MDR) strains of K. pneumoniae compared to strains susceptible to antimicrobials. In

conclusion, the assays developed were efficient in detecting the main genes of the bla

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

family of resistance in K. pneumoniae. The use of the pentose phosphate metabolic pathway suggests a benfical regulation of bacterial growt, and colonization in MDR K. pneumoniae strains, with may indicate the use of this pathway as a virulence mechanism in resistant strains. **KEYWORDS:** Antimicrobial resistance; multidrug-resistant; β-lactamases; qPCR; molecular diagnosis; Klebsiella pneumoniae. INTRODUCTION Bacterial resistance to antimicrobial agents is a global public health problem that leads to an increase in the cost of treatment, length of stay, morbidity and mortality of hospitalized patients, especially in intensive care units (ICU).^{1,2} In this sense, understanding the emergency mechanisms of regulation and dissemination of resistance to antimicrobial agents in the pathogenesis of bacterial colonization and/or infection can be of critical importance in preventing and controlling this problem. Klebsiella pneumoniae is a Gram-negative γ-proteobacteria bacteria, belonging to the Enterobacteriacae family, and is generally viewed as an opportunistic microorganism, carrying several virulence factors and capable of accumulating resistance genes to various classes of antimicrobials. It is commonly related to cases of colonization and/or healthcare-associated infections (HAIs), and has been identified as an etiological agent in pneumonia, urinary tract infections (UTI), soft tissue and surgical wound infections, bacteremia, and sepsis.³ It is estimated that K. pneumoniae is responsible for approximately 10% of all

cases of HAIs, and of these, 32.8% are caused by strains resistant to multiple

antimicrobial drugs. However, studies indicate that the rate of isolated strains presenting resistance to antimicrobials has increased over the years.^{4,5}

K. pneumoniae has been associated with the ability to overcome colonization resistance imposed by the gastrointestinal microbiota⁶ and has been reported as an emerging Multidrug-Resistant microorgananism of emergency priority by the World Health Organization (WHO) for the development of new therapies.⁷ Epidemiological data have demonstrated that *K. pneumoniae* can translocate from the gastrointestinal tract to other sterile sites of the same host or other patients through the fecal-oral route. What makes clear the clinical relevance of this microorganism. ⁸

One of the most likely causes of the increasingly frequent emergence of bacterial strains resistant to one or more antibiotics is the excessive and sometimes incorrect use of antimicrobials. The relatively long time required to identify the pathogen by traditional methods, as well as for the results of the antimicrobial susceptibility test (AST), forces the clinician to use broad-spectrum drugs empirically, increasing selective pressure, which ends up benefiting pathogens genetically capable of adapting to the adverse environment.^{1,9}

Possible answers to reduce the time needed to obtain a resistance profile, and to investigate new approaches in treatment, is the development of molecular methodologies, that can make the identification of resistance faster, and also be more sensitive than the traditional methodologies. And the investigation of metabolic differences between sensitive and resistant strains, that can lead to metabolites or pathways that can be used as targets for the development of new treatments and strategies for dealing with multidrug-resistant (MDR) microorganisms. 11-12

Beta-lactams are the class of antimicrobials most affected by resistance in general, which is conferred in gram-negatives, mainly by the *bla* gene family, this group of genes encodes enzymes called beta-lactamases, which are capable of neutralizing the action of beta-lactams through hydrolysis of the beta-lactam ring.¹³⁻¹⁵

In this study it was investigated the phenotype of resistance, the genotypic profile of the *bla* family of β-lactamases, and the metabolic differences between sensitive and MDR *K. pneumoniae* strains, isolated from patients admitted to the ICU in a university hospital in the city of Fortaleza-CE, Brazil.

We aim to develop a molecular assay, capable of identifying all variants of the most relevant genes of the *bla* family, these being: *bla*SHV, *bla*TEM, *bla*NDM, *bla*KPC, *bla*GES and *bla*CTX-M. In addition, also was included the most epidemiologically relevant variants of the *bla*-OXA subfamily. Thus, creating a set of primers capable of detecting the presence of hundreds of resistance genes with a reduced number of

down regulated in sensitive and MDR strains of K. pneumoniae, both from the

reactions. Were also investigated the main differences between the metabolites up and


intracellular medium and the supernatant among themselves and in comparison, with

the control medium.

RESULTS

Selection of bacterial samples. A total of 249 samples of Gram-negative bacteria resistant to beta lactam antimicrobials were collected from 04/23/2019 to 05/29/2021, those were identified, and the most prevalent microorganism found was *Klebsiella pneumoniae* 48.99% (122/249).

Identification of the phenotypic profile of beta-lactams resistance of *K. pneumoniae* strains. The bacteria isolates included in the study were tested against a wide range of beta-lactams drugs, and the presence of a high percentage of isolates resistant to these drugs was verified, which included <u>Penicillins</u>: ampicillin/sulbactam (92.00%) and piperacillin/tazobactam (88.46%), <u>Cephalosporins</u>: cefepime (83.02%), cefoxitin (73.68%), ceftazidime (86.54%), ceftazidime/avibactam (11.76%), ceftriaxone (83.02%), cefuroxime (90.38%) and cefuroxime axetil (81.82%) and <u>Carbapenems</u>: ertapenem (44.00%), imipenem (71.70%) and meropenem (69.81%), as shown in Figure 1.



102

103

104

105

Figure 1. Prevalence of *K. pneumoniae* isolates resistant to the beta-lactams evaluated (Penicillins, Cephalosporins and Carbapenems), demonstrating a phenotypic profile of resistance to multiple beta-lactams drugs, in approximately 70% of the isolates, with the exception of ceftazidime/avibactam and ertapenem.

106 **Primers design.** After selection on the platforms: Comprehensive Antibiotic 107 Resistance Data-base (CARD) and National Center for Biotecnology and Information 108 (NCBI, USA), and subsequent compilation and analysis of FASTA sequences, it was 109 possible to identify consensus sequences common to all sequences available in the 110 databases for each of the genes included in the study: blaSHV (N = 156), blaTEM (N = 111 167), blaNDM (N = 27), blaKPC (N = 208), blaGES (N = 25), and blaCTX-M (N = 144). 112 Except for the blaOXA gene, for which the most clinically relevant sequences were used (N = 203).113 114 The blaCTX-M and blaOXA genes, due to its diversity and high degree of 115 genetic variation between homologous sequences, were grouped into clades, and 116 divided into groups. the blaCTX-M gene group was named according to the 117 international standardization for this gene with the CTX-M 1like been divided into two 118 groups due to its high number or sequences and the genetic variation between them. 119 CTX-M 1.1like (N = 42), CTX-M 1.2like (N = 16), CTX-M 2like (N = 23), CTX-M 8like (N = 120 14) and CTX-M 9like (N = 49), while the blaOXA gene was divided into the OXA-23like 121 (N = 25), OXA-24/40like (N = 8), OXA-48like (N = 17) and OXA-51like (N = 153), as can 122 be seen in **Figures 2** and **3**.




Figure 2. Cladogram of the blaOXA subfamily showing the most epidemiologically relevant groups, covered by the primers developed, and the percentage of sequences identifiable by each primer in comparison with the total number of the blaOXA family (N = 441) at the time of publication of this work.




Figure 3. Cladogram with all sequences from the blaCTX-M subfamily divided into groups, illustrating the identifiable sequences, and the percentage of sequences detectable by each primer in comparison with the total number of the blaCTX-M family (N = 144) until the time of publication of this work.

A total of 14 pairs of primers were developed, which together have the capacity to detect 929 variants of resistance genes belonging to the *bla* gene family. The primer sequences for genes with conserved and non-conserved sequences can be found in **Tables 1** and **2**, respectively.

Table 1. Primer sequences for conserved genes

	Number of			
Name of		Primer	Sequence	Primer
aana	variations	n 2 n 2		size
gene	detectable	name		Size
		SHV-F	ATTATCTCCCTGTTAGCCACCC	22
blaSHV	156	CIND	GTTTA A TTTGCTCA AGCGGCTG	22
		SH V-K	GITTAATITIGC ICAAGCGGCTG	22
		TEM-F	ACCCAGAAACGCTGGTGAAA	20
blaTEM	167			
		TEM-R	GGGGCGAAAACTCTCAAGGA	20
		NDM-F	GAAGCTGAGCACCGCATTAG	20
blaNDM	27			
		NDM-R	CCATTTGCTGGCCAATCGTC	20
		KPC E	TCGCGGAACCATTCGCTAAA	20
blaKPC	208	Ki C-i	regeggaacearregeraan	20
		KPC-R	GAATGAGCTGCACAGTGGGA	20
blaGES	25	GES-F	GCCCAGGAGAGAGATTACGC	20
oinges	23	GES-R	CTTGACCGACAGAGGCAACT	20

Table 2. Primer sequences for non-conserved genes, divided into clades.

143

144

N	Name of gene		Primer		Primer
			name	Sequence	size
	blaCTX-M 1.1like	42	CTXM1.1L-F	GATTGCGGAAAAGCACGTCA	20
blaCTX-M		-	CTXM1.1L-R	TTCATCGCCACGTTATCGCT	20
	blaCTX-M 1.2like	16	CTXM1.2L-F	CGCCGCTGATTCTGGTCA	18
		-	CTXM1.2L-R	TGACGATTTTAGCCGCCGAC	20

ATGGCGCAGACCCTGAAAAA	CTXM2L-F	23	blaCTX-M 2like	
CTGCCGGTTTTATCGCCCA	CTXM2L-R			
CGCTCAACACCGCGATCC	CTXM8L-F	14	hlaCTX-M 8like	
ATCCCCGACAACCCACGAT	CTXM8L-R	11	owerk mount	
CGTGGCTCAAAGGCAATACG	CTXM9L-F	49	hlaCTY-M 9like	
TCTGTTGCGGCTGGGTAAAA	CTXM9L-R	1)	oiuCIX-WI June	
GCTCTAAGCCGCGCAAATAC	OXA23L-F	24	blaOX∆-23like	
TGACCTTTTCTCGCCCTTCC	OXA23L-R	24	ouoxx-25uxc	
TGCCGATGACCTTGCACATA	OXA24/40L-F	8	blaOXA-24/40like	
CCATTAGCTTGCTCCACCCA	OXA24/40L-R			blaOXA
'GGTAGCAAAGGAATGGCAAG	OXA48L-F	17	hlaOXA-48like	
GGGCGATCAAGCTATTGGGA	OXA48L-R	17	UMOAA-HUME	
GATCGGCCTTGAGCACCATA	OXA51L-F	150	MaOVA E1111-	
GCCATAACCAACACGCTTCA	OXA51L-R	153	viaUXA-5111ke	
		153	blaOXA-51like	
	CTGCCGGTTTTATCGCCCA CGCTCAACACCGCGATCC ATCCCCGACAACCCACGAT CGTGGCTCAAAGGCAATACG TCTGTTGCGGCTGGGTAAAA GCTCTAAGCCGCGCAAATAC TGACCTTTTCTCGCCCTTCC TGCCGATGACCTTGCACATA CCATTAGCTTGCTCCACCCA CGGTAGCAAAGGAATGGCAAG GGGCGATCAAGCTATTGGGA GATCGGCCTTGAGCACCATA	CTXM2L-R CTGCCGGTTTTATCGCCCA CTXM8L-F CGCTCAACACCGCGATCC CTXM8L-R ATCCCCGACAACCCACGAT CTXM9L-F CGTGGCTCAAAGGCAATACG CTXM9L-R TCTGTTGCGGCTGGGTAAAA OXA23L-F GCTCTAAGCCGCGCAAATACC OXA23L-R TGACCTTTTCTCGCCCTTCC OXA24/40L-F TGCCGATGACCTTGCACATA OXA24/40L-R CCATTAGCTTGCTCCACCCA OXA48L-F GGTAGCAAAGGAATGGCAAG OXA48L-R GGGCGATCAAGCTATTGGGA OXA51L-F GATCGGCCTTGAGCACCATA	23 CTXM2L-R CTGCCGGTTTTATCGCCCA 14 CTXM8L-F CGCTCAACACCGCGATCC 14 CTXM8L-R ATCCCCGACAACCCACGAT 49 CTXM9L-F CGTGGCTCAAAGGCAATACG CTXM9L-R TCTGTTGCGGCTGGGTAAAA OXA23L-F GCTCTAAGCCGCGCAAATAC OXA23L-R TGACCTTTTCTCGCCCTTCC OXA24/40L-F TGCCGATGACCTTGCACATA OXA24/40L-R CCATTAGCTTGCTCCACCCA OXA48L-F GGTAGCAAAGGAATGGCAAG OXA48L-R GGGCGATCAAGCTATTGGGA OXA51L-F GATCGGCCTTGAGCACCATA	blaCTX-M 2like 23 CTXM2L-R CTGCCGGTTTTATCGCCCA CTXM8L-F CGCTCAACACCGCGATCC CTXM8L-R ATCCCCGACAACCCACGAT CTXM9L-F CGTGGCTCAAAGGCAATACG blaCTX-M 9like 49 CTXM9L-F CGTGGCTCAAAGGCAATACG CTXM9L-R TCTGTTGCGGCTGGGTAAAA OXA23L-F GCTCTAAGCCGCGCAAATAC OXA23L-R TGACCTTTTCTCGCCCTTCC OXA23L-R TGCCGATGACCTTGCACATA blaOXA-24/40like 8 OXA24/40L-F TGCCGATGACCTTGCACATA OXA48L-F GGTAGCAAAGGAATGGCAAG OXA48L-F GGTAGCAAAGGAATGGCAAG OXA48L-R GGGCGATCAAGCTATTGGGA OXA48L-R GGGCGATCAAGCTATTGGGA OXA51L-F GATCGGCCTTGAGCACCATA

In silico primers validation. The parameters obtained for each primer after analysis using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite (SMS): PCR Primer Stats software are available in **Table 3**.

146

147

148

149

150

Table 3. Parameters obtained by *in silico* validation of the developed primers.

Primer name	Tm (C°)	GC%	Self	Self 3'	Produt
	,		complementarity	complementarity	length
SHV-F	59,2	50,0	3	0	
					70
SHV-R	59,3	45,4	5	3	•
TEM-F	60,1	50,0	4	0	110
	SHV-F SHV-R	SHV-F 59,2 SHV-R 59,3	SHV-R 59,3 45,4	Primer name Tm (C°) GC% complementarity SHV-F 59,2 50,0 3 SHV-R 59,3 45,4 5	Primer name Tm (C°) GC% complementarity complementarity SHV-F 59,2 50,0 3 0 SHV-R 59,3 45,4 5 3

	TEM-R	59,9	55,0	2	1	
blaNDM	NDM-F	59,3	55,0	5	1	86
otandwi	NDM-R	60,1	55,0	6	2	
blaKPC	KPC-F	60,3	50,0	4	2	128
oluxi C	KPC-R	60,3	55,0	5	1	126
blaGES	GES-F	59,9	60,0	3	2	94
oiuGE3	GES-R	59,9	55,0	3	2	
blaCTX-M 1.1like	CTXM1.1L-F	59,7	50,0	4	1	87
014C1X-141 1.111KC	CTXM1.1L-R	60,1	50,0	4	2	
blaCTX-M 1.2like	CTXM1.2L-F	60,1	61,1	3	2	90
014C1X-141 1.211KC	CTXM1.2L-R	61,0	55,0	3	3	
blaCTX-M 2like	CTXM2L-F	60,5	50,0	4	0	155
owerk minime	CTXM2L-R	60,7	57,8	4	1	
blaCTX-M 8like	CTXM8L-F	61,5	66,6	4	2	197
owerk monke	CTXM8L-R	60,9	57,8	3	2	
blaCTX-M 9like	CTXM9L-F	59,9	55,0	3	2	180
	CTXM9L-R	60,1	50,0	3	0	
blaOXA-23like	OXA23L-F	60,0	55,0	4	0	129
0,000,012	OXA23L-R	59,9	55,0	2	0	_ 12)
blaOXA-24/40like	OXA24/40L-F	59,7	50,0	4	2	177
	OXA24/40L-R	60,0	55,0	4	0	
blaOXA-48like	OXA48L-F	59,8	52,3	3	0	183
	OXA48L-R	59,8	55,0	4	0	_ 100
blaOXA-51like	OXA51L-F	59,8	55,0	4	2	199

Testing, optimization, and standardization of *in vitro* reactions. All primers were tested using positive controls developed *in house*, and it was possible to verify that the ideal annealing temperature (Ta) for the developed primer pairs was 61°C, except for the primer referring to the *blaNDM* gene, for which the ideal Ta was 64°C. The reactions were then evaluated for their specificity and stability by checking the Melting temperature (Tm). The melting curves are available in the supplementary material Figure S1.

Efficiency curve It was found that all tested primers presented an efficiency rate \geq 93.21 and \leq 101.28%, $R^2 \geq$ 0.99, and detection limit between \approx 2 and \approx 13 copies/ μ L as shown in Table 4.

Table 4. Results of the efficiency curves of the developed primers.

Gene name	Efficiency	Correlation	Threshold	Detection limit	Melting Peak
Gene name	(%)	coefficient (R2)	Threshold	(Copies/μL)	(Tm°C)
blaSHV	96,15	0,992	0,60	≈2	86,7
blaTEM	95,32	1,000	0,70	≈2	81,5
blaNDM	99,90	0,999	0,48	≈2	85,7
blaKPC	100,44	0,992	0,24	≈2	85,7
blaGES	100,21	0,997	0,27	≈2	81,7
blaCTX-M 1.1like	95,75	0,999	0,40	≈13	84,3
blaCTX-M 1.2like	100,82	0,994	0,32	≈13	83,2
blaCTX-M 2like	98,09	0,998	0,30	≈2	86,4
blaCTX-M 8like	95,32	1,000	0,10	≈13	88,4
blaCTX-M 9like	97,82	0,996	0,10	≈2	89,0

blaOXA-23like	99,51	1,000	0,15	≈2	78,4
blaOXA-24/40like	101,82	0,988	0,15	≈13	78,7
blaOXA-48like	93,21	1,000	0,20	≈13	80,29
blaOXA-51like	95,51	0,993	0,55	≈2	82,0

Identification of the genetic resistance profile of *K. pneumoniae* isolates. The 122 *K. pneumoniae* isolates were tested against the 14 pairs of primers developed, and it was possible to verify a high prevalence of beta-lactam resistance genes among the isolates analyzed. The most prevalent genes detected were, respectively: *bla*KPC (95.90%); *bla*SHV (94.26%); *bla*CTX-M 1.2*like* (88.52%); *bla*CTX-M 2*like* (83.61%); *bla*CTX-M 1.1*like* (80.33%); *bla*TEM (80.33%); *bla*NDM (33.61%); *bla*OXA-23*like* (28.69%); *bla*GES (20.49%); *bla*OXA-51*like* (15.57%); *bla*CTX-M 9*like* (13.93%); *bla*CTX-M 8*like* (12.30%); *bla*OXA-24/40*like* (11.48%) *and bla*OXA-48*like* (3.28%). The results can be seen in Figure 4A, grouped according to Ambler's classification.

It is important to note that not all variants of each group of genes analyzed belong to a single class in the Ambler's classification, such as *bla*TEM and *bla*SHV genes, where not all variants have activity as extended spectrum beta-lactamases (ESBL) for example, however, due to the grouping of all sequences in a single primer, the separation of these sequences into other groups would be impossible, so the grouping of genes was carried out globally in a way that covered the mains classification of the subfamily in question.

Through the data obtained by the qPCR reactions developed, it was also possible to verify that the isolates analyzed during this study had the presence of

several genes belonging to the bla family accumulated, with values varying from 3 to

12 of the tested genes, present per isolate, as shown in **Figure 4B**.

182

183

184

185

186

187

188




Figure 4. (A) Prevalence of beta-lactams resistance genes among the analyzed isolates, grouped according to the Ambler classification. **(B)** The percentage of *K. pneumoniae* isolates showing accumulation of genes encoding beta-lactamases belonging to the *bla* family.

Comparisons of metabolomic profiles of *K. pneumoniae* isolates. In total, 241 metabolites were identified in positive mode and 116 metabolites identified in negative mode. Among these, 309 metabolites were identified by combining data from both acquisition modes (positive and negative) without redundancy. The principal component analysis (PCAs) and the heatmap analysis between the metabolites in supernatant of susceptible *K. pneumoniae* versus the control culture medium showed complete separation of the main vectors of the PCA plots and differential upregulation or downregulation between the two experimental groups (Figure 5). Among these metabolites, 25 were upregulated or downregulated. Interestingly, metabolites related to the synthesis of nitrogenous bases, protein synthesis and energy supply to the bacterial cell are significantly increased in supernatant derived from susceptible *K. pneumoniae* (Figures S2, S3 and S4). Similar findings were detected between MDR *K. pneumoniae* strains and control culture medium (Figures S5, S6 and S7).




Figure 5. Comparison between susceptible *K. pneumoniae* supernatants (Sens) versus culture media. **(A)** Plot of the principal component analysis (PCAs) and **(B)** the heatmap of the comparison of metabolites between the supernatant of susceptible *K. pneumoniae* versus the control culture media.

The principal component analysis (PCAs) and the heatmap analysis of metabolites in supernatants from *K. pneumoniae* MDR versus susceptible isolates exhibited complete separation of the main vectors of the PCA plots (**Figure 6A**) and differences on levels of metabolites (**Figure 6B**). The analysis of deregulated metabolites between *K. pneumoniae* MDR versus susceptible isolates showed increased N-fructosyl isoleucine in the MDR *K. pneumoniae* isolates (p< 0.05, **Figure 6C**).




Figure 6. Comparison of supernatants from *K. pneumoniae* MDR versus susceptible (Sens). **(A)** Plots of the principal component analysis (PCAs) and **(B)** the heatmap of the comparison of metabolites between the supernatant of *K. pneumoniae* MDR versus

susceptible (Sens). **(C)** Plots of dysregulated metabolites between supernatants of *K. pneumoniae* MDR and susceptible.

Analysis of the intracellular metabolites of susceptible versus MDR K. pneumoniae showed differences in the PCAs vectors (**Figure 7A**), heatmap (**Figure 7B**). and increased N-fructosyl isoleucine levels in the MDR K. pneumoniae isolates (p<0.05, **Figure 7C**). **Figure 8** shows the PCAs and heatmap plots of supernatant from sensitive and MDR K. pneumoniae.




Figure 7. Comparison of Intracellular media of *K. pneumoniae* MDR versus susceptible (Sens). **(A)** Principal Component Analysis (PCAs) plots and **(B)** Heatmap of the Intracellular Environment of *K. pneumoniae* MDR and susceptible. **(C)** Plots of dysregulated metabolites between the intracellular media of *K. pneumoniae* MDR and susceptible.




Figure 8. Comparison of *K. pneumoniae* Multidrug-Resistant (MDR) supernatants versus culture media. (A) Principal component analysis (PCAs) plots and (B) Heatmap of the supernatant of *K. pneumoniae* susceptible and MDR. Observe the separation of the main vectors of the (PCAs) plots and details of the differences in the heatmap between the two experimental groups.

DISCUSSION

During the period analyzed in the study, 249 bacterial isolates resistant to two or more class of antimicrobials used in TSA were identified. Of these resistant isolates, 48.99% (122/249) belonged to the species *Klebsiella pneumoniae*, being this microorganism the most prevalent among those identified.

This data is consistent with what is seen in Egypt, where when evaluating 186 samples from Cairo hospitals, *K. pneumoniae* was found as the main gram-negative bacterial agent representing 40.9% (76/186) of the identified microorganisms, and

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

among these isolates obtained, a high prevalence of resistance to beta-lactams, quinolones, and sulfonamides was identified (89.4%, 89.4% and 87.1%) respectively.¹⁶ The phenotypic profile of the K. pneumoniae isolates analyzed in the present study demonstrated high levels of resistance to the beta-lactams drugs tested in all classes evaluated (penicillins, cephalosporins and carbapenems). Although the resistance profile of strains may vary depending on the test location and the conditions to prevent spread, the resistance to beta-lactams among Enterobacteriaceae is known to be high, as demonstrated in a study carried out in Brazil, with samples of human and veterinary origin where 62.85% and 54.28% of *Enterobacteriaceae* isolated were resistant to amoxicillin/clavulonate and cefazolin respectively. 17 In studies carried out in Egypt, evaluating isolates of K. pneumoniae from food sources, and in Tunisia and Iran evaluating isolates from hospital samples, the presence of high resistance to beta-lactams can be verified for ampicillin/sulbactam (95.5%), (93%), (95.5%),ceftazidime cefoxitin cefotaxime $(93.2\%)_{i}$ amoxicillin/clavulonate (86.4%), ertapenem (90.9%) and temocillin (84.0%). 18, 19, 20 Likewise, in a study carried out with 102 isolates obtained from two Portuguese hospitals, the presence of resistance rates > 90% was verified for all beta-lactam drugs tested, except for cephalosporins: cefoxitin (40.2%), cefotetan (68.6%) and carbapenems: ertapenem (23.5%), imipenem (32.4%), meropenem (34.3%) and doripenem (33.3%).²¹ This result is consistent with that found in this study, where the beta-lactam drugs that showed a lower resistance rate belonged to the same classes mentioned, namely: cefoxitin (73.68%), ceftazidime/avibactam (11.76%), ertapenem (44.00%), imipenem (71.70%) and meropenem (69.81%).

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

Resistance to beta-lactams is conferred in Gram-negatives mainly by genes belonging to the bla family. This group of genes is composed of dozens of subfamilies and hundreds of genetic subvariants in each family, the molecular panel developed managed to encompass some of the most predominant and clinical relevant subfamilies among clinical isolates, identified in several studies, namely: blaSHV, blaTEM, blaNDM, blaKPC, blaGES, blaCTX-M and blaOXA.22-24 After analysis using the Primer-BLAST® (NCBI, USA) and Primer Stats Sequence Manipulation Suite (SMS) software, it was verified that the developed primers have specificity for the sequences used in the alignment, melting temperature (Tm) between 59 29 °C and 61.55 °C, GC% concentration varying between 45.45% and 66.67% in addition to having complementary base numbers ≤ 6 in the analysis of dimer and hairpin formation. The values obtained for these parameters therefore demonstrate that they are compatible with those obtained in reference studies.^{25–27} Due to the high number of sequences included in the development of primers, many of the alternatives obtained through Primer-BLAST® (NCBI, USA) did not meet the stability requirements regarding the formation of secondary structures (selfannealing and hairpins), In order to choose the options with the best performance in relation to these parameters, the GC clamp was relaxed so that the primers SHV-F, SHV-R, CTXM1.2L-R and CTXM2L-R obtained 4 G or C residues within the last 5 nucleotides of the 3' end, the primers CTXM9L-R and CTXM2L-F did not present C or G residues within the last 5 nucleotides of the sequence. This fact could lead to the formation of strong bonds and increase the Tm value in primers with more than 3 terminal GC residues, and cause inhibition of amplification due to the presence of weak bonds when there is an absence of terminal

CG ^{28,29}. Such changes, however, were not evident when the primers were tested *in* vitro.

The variety of sequences detectable by the developed primers makes in vitro validation using positive controls for all sequences virtually impossible. In silico analysis allowed the evaluation of all tested sequences quickly, cheaply and constantly, since the developed primers can be tested against new variants of the target genes.^{26–28}

In vitro analyzes were carried out using SYBR Green master mix, the melting curve was therefore used as a parameter to evaluate the specificity of the reactions. And it was verified that for all tested primers a single melting peak was found, indicating the formation of a single amplicon. And excluding the presence of secondary structures (primer dimers and hairpins).

The analysis of the melting curve and Tm is considered fundamental to test the specificity of reactions that use SYBR Green as an amplification indicator, because unlike reactions that use specific probes, which emit fluorescence only when the reaction occurs at the expected target. The SYBR Green works by binding to any double-stranded fragment formed, thus emitting fluorescence. Therefore, only by analyzing the melting curve and the specific Tm of the amplicon is it possible to determine whether the reaction was successful.^{29–31}

The efficiency curve and its parameters were used to evaluate the performance of qPCR reactions, by checking how efficiently the targets were amplified in each PCR cycle.^{32, 33} When evaluating the activity of primers in qPCR reactions using the efficiency curve, it was found that all primers analyzed in this study presented efficiency values >90% and <110% and correlation coefficients (R²) >0.9, thus being in accordance with the parameters presented in reference documents present in the

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

literature.³³ It was also possible to verify a high detection capacity even at low concentrations of genetic material since the detection limit obtained varied between ≈2 and ≈13 copies/µL of the target gene used as control. Several studies report the growth in the prevalence of the blaKPC gene, with this being the most detected carbapenemase worldwide. The values found vary according to the location. The main variant of the blaKPC gene detected is blaKPC-2, with prevalence values varying from 1.2% to 51.6% among enterobacteria in studies carried out in the United States of America and China respectively.^{34, 35} This gene is found more frequently in isolates of K. pneumoniae, many studies report high prevalence rates in this species ranging from 17.2% to 64.6%. 4, 35, 36, 37 In a study conducted in an intensive care unit in the northeast reagion of Brazil, it was shown that of 25 isoates of K. pneumoniae obtained during the research, 100% exhibited the presence of the blaKPC gene. 38 The values found in this paper for the blaKPC gene may reflect the fact that the primer developed detected all variants of the gene, as well as the higher rates of resistance usually found in intensive care unities (ICU).³⁹ The results found in this work are in agreement with other studies performed at the northeast of Brazil³⁸, what can represent an endemic presence of the blaKPC gene among *K. pneumoniae* isolates in this Brazilian region. The blaTEM and blaSHV genes were the first ESBL identified, and together with the blaCTX-M subfamily of genes are considered the most prevalent ESBL's. These genes are widely distributed among enterobacteria; in a study carried out in Sudan, the blaTEM, blaCTX-M and blaSHV genes were identified in 86.0%, 78.0% and 28.0% respectively.40

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

In a work carried out in ICUs in Chile, it was possible to verify the presence of these genes with prevalence rates of 81.0%, 84.7% and 73.0% for blaSHV, blaCTX-M-1 and blaTEM, where a higher prevalence of the blaSHV gene was found when compared to the study carried out in Sudan.41 In Brazil, it is also possible to verify the presence of high prevalence rates of these genes among K. pneumoniae isolates from ICU, with studies indicating rates of 100%, 96% and 72% for blaTEM, blaSHV and blaCTX-M1 respectively. 38 These results agree with those evidenced in this study for the K. pneumoniae isolates tested. The blaNDM gene is considered the second most prevalent carbapenemase producing gene in the world, behind only the blaKPC gene. In this study, the presence of the metallo beta-lactamase NDM gene was verified in (33.61%) of the isolates. Similar results were evidenced in China, where the presence of this gene was verified in 35.7% of 935 carbapenem-resistant enterobacteria tested.³⁴ The prevalence found in this study for the blaNDM gene is still below what was found in other studies carried out in Brazil in the states of São Paulo and Sergipe, where the authors found a prevalence of 70 and 50% respectively in K. pneumoniae isolates. 42, 43 Regarding oxacillinases, a low prevalence of the blaOXA-48like gene was observed (3.28%). This gene may be present in all Enterobacteriaceae; however, it is more prevalent in strains of *K. pneumoniae*.²¹ The values found in the literature for the presence of this gene in Enterobacteriaceae are very divergent, with marked variations related to the location of the analysis, these values vary from 7.3% in China to 83.3% in Morocco.^{34, 44} In a study conducted in Brazil where 4,451 isolates of Enterobacteriaceae were analyzed, the

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

blaOXA-48like gene was detected in only 2.5% of the isolates tested.45 In this way, the result obtained is compatible with what was previously identified in Brazil, and close to what is seen in China. The presence of variants of the blaOXA gene (bla-OXA-51like (15.57%), blaOXA-24/40like (11.48%) and blaOXA-23like (28.69%)) was also observed in the isolates tested, these genes were long considered exclusive to strains of Acinetobacter baumannii, however studies have demonstrated the presence of these genes in other Enterobacteriaceae, including K. pneumoniae. 46 Results regarding the prevalence of these genes in strains of K. pneumoniae are still scarce, however, in a study conducted in Bahrain in the Persian Gulf, the blaOXA-51 and blaOXA-23 genes were identified respectively in 45.8% and 41.6%. % of *K. pneumoniae* isolates analyzed.⁴⁷ It is believed that many of the beta-lactamases that today can be found contained in mobile genetic elements had their origin in chromosomes of other bacteria, as occurred with the SHV type variants that derived from the K. pneumoniae chromosomal SHV-1, and the CTX-M type variants that appear to have originated from the chromosomal CTX-M of Kluyvera spp²¹. This change in the presentation of these genes, from chromosomal to mobile elements, may explain the appearance of genes such as chromosomal blaOXA present in A. baumannii strains on plasmids widespread in other species. It was possible to verify the presence of isolates presenting multiple genes coding for beta-lactamases, from 3 to 12 of the genes analyzed. Studies point to a high prevalence among Enterobacteriaceae of the accumulation of genes from the bla family, mainly genes belonging to ESBL, OXA beta-lactamases and carbapenemases such as

blaKPC and blaNDM. This phenomenon is more evident in hospital environments

where selective pressure favors microorganisms carrying resistance genes and where there is a high rate of sharing of these genes.^{48,49}

Investigations into metabolomic modulation in *K. pneumoniae* have demonstrated a promising area for understanding resistance to antimicrobial agents, developing new therapies, and for studying bacterial virulence. For example, significant inhibition of the pentose phosphate pathway, citrate cycle, amino acid and nucleotide metabolism was observed to be beneficial during treatment of MDR *K. pneumoniae* using the bacteriophage-polymyxin combination, showing the potential for new therapeutic targets and pathways metabolic processes to improve the effectiveness of treatment with available antimicrobial agents.^{50,51}

This study is in accordance with others that highlighted the importance of the pentose phosphate pathway in MDR *K. pneumoniae* strains.⁵⁰ This finding was present in both media, supernatant and intracellular in MDR isolates, compared with *K. pneumoniae* isolates susceptible to antimicrobial agents. The significant presence of the metabolic N-fructosyl isoleucine (C12H23NO7; MW: 293.316) in the supernatant and intracellular media of *K. pneumoniae* MDR indicates the expression of the fructose degradation enzyme gene (*frwC*; fructose-specific phosphotransferase system), which is involved in regulating bacterial growth, virulence and overcoming colonization resistance due to the use of alternative carbon source from fructose.^{52, 53}

Metabolomics has proven to be a promising approach in the study of antimicrobial resistance. Its use allows for the comprehensive investigation of metabolic changes associates with different resistance mechanisms, such as alternative energy-obtaining pathways, modifications that alter the cell wall, communication

between bacterial cells, and changes in the colonization capacity of these microorganisms. 54, 55

The identification of these metabolic differences plays an important role in the Discovery of new therapeutic targets and strategies for investigating the reversal of resistance in these pathogens. 55-57 The combination of genetic and metabolomic techniques therefore contributes to a comprehensive view of resistance mechanisms in bacteria. 56.57

The presence of N-fructosyl isoleucine in resistant strains, and the metabolic benefit that its presence appears to generate in increasing colonization capacity, together with the selective pressure found in ICU environments due to the constant use

benefit that its presence appears to generate in increasing colonization capacity, together with the selective pressure found in ICU environments due to the constant use of antimicrobials may be related to the high rates of resistant isolates disseminated among patients in this environment.

The metabolic evaluation in turn points to a metabolic advantage in resistant strains compared to sensitive ones, which goes beyond the resistance capacity itself.⁵⁸

This study has some limitations, such as the exploration of only *bla* family genes, limiting a broader understanding of resistance mechanisms to antimicrobial agents. On the other hand, it presents a broad methodology for exploring the important *bla* family genes most associated with resistance to beta-lactams in *K. pneumonia*. The metabolic findings showed a specific indication that suggests an association with virulence and better proteomic studies will be necessary to associate with potential mechanisms of resistance to antimicrobial agents. Furthermore, additional preclinical studies will be necessary to determine and more specifically validate the virulence associated with the pentose phosphate pathway in *K. pneumoniae*.

CONCLUSIONS

The results of this work show the high prevalence of resistance to antimicrobial agents in isolates of *K. pneumoniae* within the hospital environment, and that this phenotypic pattern exhibited a great concern as it limits the therapeutic options available, directly implicating the patient's prognosis.

The assays developed were within the quality criteria for qPCR reactions using SYBR Green master mix and were efficient in detecting the beta-lactams resistance genes from the *bla* family evaluated in this study. The genotypes of the *bla* genes obtained are relevant and worrying for the local hospital scenario, and compatible with the identified phenotypic profile.

The identification of the metabolic N-fructosyl isoleucine in the supernatant and intracellular media of *K. pneumoniae* MDR indicates the expression of the fructose degradation enzyme gene, which is involved in regulating bacterial growth, virulence and overcoming resistance to colonization due to the use of an alternative carbon source from fructose.

MATERIALS AND METHODS

Obtaining bacterial isolates and identification. For the following study, samples were collected, as part of the clinical investigation of patients admitted to the ICU of a tertiary care health unit in the city of Fortaleza-CE. Were included in the work those microorganisms that were identified as gram-negative bacteria, resistant to two

or more groups of antimicrobial agents, including subclasses of β -lactams, fluoroquinolones and aminoglycosides.

The bacterial isolates were identified and tested for their susceptibility to antimicrobials using the automated VITEK® 2 Compact method (BioMérieux, Marcy l'Etoile, France), according to the manufacturer's recommendations. Minimum inhibitory concentrations were interpreted according to the Clinical and Laboratory Standards Institute (CLSI). For quality control of sensitivity tests, strains from the American Type Culture Collection (ATCC) were used. Specimens that had a resistance profile that fit the research objectives were included in the study.

Extraction of bacterial DNA. To extract the genetic material, the Wizard Genomic DNA Purification extraction and purification kit (Promega, Madison, USA) was used, according to the manufacturer's recommendations.

After extraction, all samples were then quantified by spectrophotometry using the NanoDropTM 2000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and stored in a -80°C freezer until used in the experiments.

Selection of genes used in the study and obtaining FASTA sequences. For greater coverage of the genetic profile of resistance to β-lactams in gram-negatives, genes with relevant prevalence epidemiology, belonging to the *bla* gene family, were part of the study, and these included the genes: *blaSHV*, *blaTEM*, *blaNDM*, *blaKPC*, *blaGES*, *blaCTX-M* and *blaOXA*. The sequences used were obtained through the Comprehensive Antibiotic Resistance Database (CARD) and National Center for Biotecnology information (NCBI) platforms, which compiles and organizes the

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

resistance gene sequences available in GenBanck, the list of identifiable sequences is available in the supplementary material Text S1. Primer design. To design the primers, all variant sequences of each gene included in the study available on the CARD and NCBI platforms were gathered, the sequences were aligned using the Clustal Omega software, and the alignments were analyzed using the SnapGene software. Consensus regions with homology ≥95% were selected and these were used to design the primers using the Primer Blast platform from the National Center for Biotechnology and Information (NCBI, USA). The consensus sequences obtained is available in the supplementary material Text S2. Genes with few conserved regions, for which it was not possible to obtain consensus sequences with homology ≥95%, were separated into clades, and primers were then designed for the sequences by phylogenetic grouping, complying with a minimum of 95% similarity. In silico validation of the developed primers. All primers developed were validated in silico regarding their specificity, structure, formation of primer-dimers and hairpins using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite (SMS): PCR Primer Stats platforms. Testing, optimization, and standardization of primers. The reactions were standardized with the use of positive controls developed in-house, through amplification of genetic material, isolation, and purification of amplicons, originating

from isolates phenotypically resistant to beta-lactams, and negative control (water

DNase/RNase free). They were carried out using a CYBR Green master mix (Promega,

Madison, USA), the initial results were evaluated regarding the melting temperature (Tm), to confirm the specificity of the amplicons.

To determine the most efficient qPCR conditions, to reduce the existence of non-specificity and facilitate the interpretation of the results, the concentration gradient and annealing temperature (Ta) of the primers were performed. The qPCR reaction conditions included a hot start step at 95°C for 2 minutes, followed by 35 cycles consisting of a denaturation step for 15 seconds at 95°C, and an annealing/extension step for 1 minute at Ta. specific to each primer, all reactions went through a final melting curve step, with a temperature variation of 60 to 95°C with an increase of 0.05° C/sec.

A 9-point efficiency curve was performed with a dilution factor of 1:8, for each primer developed, with concentrations ranging from \approx 27,438,596 to \approx 2 (copies/ μ L), through this procedure it was possible to determine the values of threshold, evaluate the efficiency (%), the correlation coefficient (R²) and the limit of detection of each primer.

Detection of resistance-related genes by molecular biology. The *K. pneumoniae* isolates obtained in the study were tested against the developed primers. Melting curve analysis of all reactions was used to evaluate the specificity of the results of the isolates in comparison to the specific melting temperature (Tm) of the positive control.

Preparation of *K.* pneumoniae samples for metabolomic evaluation. Isolates of *K. pneumoniae* susceptible and multidrug resistant to antimicrobial agents obtained in this work were submitted for metabolomic analysis. For this experiment, seven samples of the culture supernatant were designed: one sample of the culture medium, two samples of the culture supernatant of susceptible *K. pneumoniae* (biological

replicates), four samples of the culture supernatant of multidrug-resistant *K. pneumoniae* (MDR) for untargeted metabolomics determination and analysis. Samples of the intracellular medium of the *K. pneumoniae* culture, two samples of susceptible *K. pneumoniae* (biological replicates) and four samples of MDR *K. pneumoniae* were also used for untargeted metabolomic analysis. Technical replicates were performed for susceptible media and samples to allow for a pilot statistical comparison.

Methodology for extracting *K. pneumoniae* culture supernatant. To 200 μL of *K. pneumoniae* culture medium or control medium, 800 μL of 80% methanol was added at -20 °C. The samples were vortexed and incubated at -20 °C for 2 hours for protein precipitation. The samples were centrifuged for 10 min at 4°C at 10,000 g (Benchtop refrigerated centrifuge 10k RPM Eppendorf) and the supernatants were transferred to new tubes. The samples were dried under vacuum (Speed Vac Thermo fisher) for approximately 4-5 hours. Dried samples were redissolved in 100 μL of 0.1% formic acid in water containing Metabolomics QReSS labeled heavy standards diluted 100X. (https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). A quality control (QC) was done, combining 10 μL of each sample. After the QC test in the mass spectrometer, the samples were diluted 10x to be analyzed. The injection volume of each sample was 10 μL per ionization mode.

Methodology for extractions from the intracellular medium of *K. pneumoniae* culture. To each tube, 750 μL of cold chloroform:methanol (2:1) mixture at -20 °C was added, vortexed and transferred to tubes reinforced with a ball beater. Cells were disrupted in a bead beater with steel balls for 3 min at an intensity of 5 (Bead Ruptor Elite Omni International Material). The tubes were shaken vigorously for 30 min at 4°C in a temperature-controlled thermal shaker (Thermomixer Eppendorf). 400 μL of water

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

was added, shaken vigorously, and centrifuged for 10 min at 10,000 rpm (Benchtop refrigerated centrifuge 10k RPM Eppendorf) for phase separation. The upper aqueous/methanolic phase was saved as a mixture of soluble metabolites and transferred to Eppendorf tubes. Soluble metabolites were dried under vacuum for 3-4 h (Speed Vac Thermo Fisher). Before running, samples were reconstituted in 100 μL of 0.1% formic acid in water containing 100X diluted Metabolomics QReSS labeled heavy standards (https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). The QC sample was prepared with 10 µL of each sample. The injection volume of each sample was 10 µL. Analysis by Ultra Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry (UPLC-MS/MS) of metabolites. MS data were acquired on the Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system. Soluble metabolites were separated using a Waters BEH C18 column (100 x 2.1 mm, 1.9 µm) operated at 30 °C and a flow rate of 250 μL/min. Mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in 90% methanol. Bulk scan range: 67-1000 at 120,000 resolutions with 0.6 sec scan range. The 10 most intense ions in each full scan were selected for fragmentation and MS2 spectra were acquired at a resolution of 30,000 and scaled collision dissociation fragmentation energy of 25, 30, 35 was used. **UPLC** gradient. The total time used in the UPLC gradient runs was 15 minutes. The flow used was 0.250 mL/min and the following gradient in the percentage of mobile phase B was 50% at 8 min, 98% at 9 min. maintaining until a time of 13 min., ending with 0% between a time of 13.1 – 15 min.

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

Verification settings in the mass spectrum. The configurations used in the verification through the mass spectrum were orbit trap of the mass spectrum in the master scan, with an orbitrap detector with a resolution of 120,000. We used quadrupole isolation with a scanning range between 67-1000 m/z, using the frequency lens at 60%. The automatic gain control target was customized and normalized to 25%. The maximum injection time mode has been customized with a maximum injection time of 50 ms. MIcroscans of 1 and profile with positive polarity. Font fragmentation has been disabled. Data acquisition, metabolic identification, and data analysis. Once the data was acquired, the samples were analyzed using the open-source software MS-DIAL. More details about software obtained here: http://prime.psc.riken.jp/compms/msdial/main.html.^{59,60} Three blank samples were included in the analysis to identify background ions and remove them later. Samples acquired using MS1 full scan used for quantification and data-dependent acquisition (DDA) mode were used for spectral identification of metabolites. Tolerance MS1 was set to 0.01 Da and MS2 set to 0.025 Da. For peak harvesting, the mass slice width was set to 0.1. For peak alignment, the maximum retention time tolerance was set at 0.5 min, the MS1 tolerance was set at 0.01. Peaks were identified by searching MS2 spectra in the public MS-DIAL database downloaded in January 2023 (324,191 records for positive mode and 64,669 entries for negative mode) using a mass tolerance of 0.01 Da for MS1 and 0.05 Gives to MSMS with an identification cutoff point of 80% http://prime.psc.riken.jp/compms/msdial/main.html#MSP. Additionally, peaks were also searched against the core Biomolecular Analysis Facility's internal IROA library

(both positive and negative mode) with a mass tolerance of 0.02 and identification

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

cutoff of 85%. The data was manually inspected and identifications without MS2 were filtered, except for identifications of the IROA molecule. Supplementary Materials: The following supporting information: Figures S1-S7; Text S1; Text S2. Figure supplement legend: Figure S1 – Primer's specificity evaluation through Melting curve: (A) SHV, (B) KPC, (C) NDM, (D) TEM, (E) GES, (F) OXA-23like, (G) OXA-24/40like, (H) OXA-48like, (I) OXA-51like, (J) CTX-M 1.1like, (K) CTX-M 1.2like, (L) CTX-M 2like, (M) CTX-M 8like e (N) CTX-M 9like. Figure S2 - Plot analysis of the 25 main metabolites from the supernatant of susceptible K. pneumoniae in general without separation by up- or down-regulation of the analytes. Note that in the supernatant of K. pneumoniae compared to the culture media, metabolites related to the synthesis of nitrogenous bases, protein synthesis and energy supply to the bacterial cell are significantly increased. Figure S3 - Plot of the analysis of the 25 main metabolites from the supernatant of susceptible K. pneumoniae, separated because they were up-regulated in relation to the control culture media. Figure S4 - Plot of the analysis of the 25 main metabolites from the supernatant of susceptible K. pneumoniae, separated because they were down-regulated in relation to the control culture media.

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

Figure S5 - Plot of the analyzes of the 25 main metabolites from the supernatant of Multidrug-Resistant (MDR) K. pneumoniae in general without separation by up- or down-regulation in the analytes. Note that in the intracellular media of K. pneumoniae compared to the culture medium, metabolites related to the synthesis of nitrogenous bases, protein synthesis and energy supply to the bacterial cell are significantly increased. Figure S6 - Plot of the analysis of the 25 main metabolites from the supernatant of K. pneumoniae MDR, separated by being up-regulated in relation to the control culture media. Figure S7 - Plot d of the analysis of the 25 main metabolites from the supernatant of K. pneumoniae MDR, separated because they were down-regulated in relation to the control culture media. **AUTHOR INFORMATION Corresponding Authors:** Aldo A.M. Lima - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, https://orcid.org/0000-0002-0299-1747 Email: <u>alima@ufc.br</u> José Kleybson de Sousa – Department of Pediatrics Gastroenterology, UVA Hospital, University Virginia, Charlottesville, Virginia 22903, United States; https://orcid.org/0000-0003-3512-484X

644

Email: <u>ztx7ex@virginia.edu;</u> 645 646 **Authors** 647 Lavouisier F.B. Nogueira - Institute of Biomedicine, Faculty of Medicine, Federal University 648 of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, 649 Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-5008-8181 650 651 Marília S. Maia - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, 652 Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department 653 Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, 654 https://orcid.org/0000-0002-7005-7841 655 Marco A.F Clementino - Institute of Biomedicine, Faculty of Medicine, Federal University of 656 Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, 657 Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. 658 https://orcid.org/0000-0002-0628-8047 659 Ila F.N. Lima - Hospital Universitário Walter Cantídio, Federal University of Ceara, 660 Fortaleza-Ceara 60430-270, Brazil. 661 Jorge L.N. Rodrigues - Hospital Universitário Walter Cantídio, Federal University of Ceara, 662 Fortaleza-Ceara 60430-270, Brazil. Luciana V.C. Fragoso - Hospital Universitário Walter Cantídio, Federal University of Ceara, 663 664 Fortaleza-Ceara 60430-270, Brazil.

It is made available under a CC-BY-ND 4.0 International license.

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

Glairta S. Costa - Hospital Universitário Walter Cantídio, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. Jose Q.S. Filho - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-9619-4553 Alexandre Havt - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-4546-2976 Deiziane V.S. Costa - Infectious Diseases and International Health, University of Virginia, Charlottesvillle, VA 22908. https://orcid.org/0000-0001-6402-8908 Lyvia M.V.C. Magalhães - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0001-6990-4903 Dilza Silva - Biomolecular Analysis Facility, School of Medicine, University of Virginia, Charlottesvillle, VA 22908. https://orcid.org/0000-0002-6519-346X Nicholas E. Sherman - Biomolecular Analysis Facility, School of Medicine, University of Virginia, Charlottesville, VA 22908. https://orcid.org/0000-0003-3206-3113 **Author Contributions:** Bibliographic review and data collection, Lavouisier F.B. Nogueira, Marília S. Maia, Marco A.F Clementino and Aldo A.M. Lima.

685 Methodology, Lavouisier F.B. Nogueira, Marília S. Maia, Marco A.F. 686 Clementino, Alexandre Havt, Ila F.N. Lima, Jorge L.N. Rodrigues, Luciana V. C. 687 Fragoso and Aldo A. M. Lima. 688 Bioinformatics, Lavouisier F.B. Nogueira and Marco A.F Clementino. 689 <u>In silico analyses</u>, Lavouisier F.B. Nogueira, Marco A.F Clementino. 690 In vitro validation of primers and sample testing, Lavouisier F.B. Nogueira, 691 Marília S. Maia. 692 Metabolomics, Datascience and data Bank, Jose Q.S. Filho; Deiziane V.S. Costa, 693 José K. Sousa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman and 694 Aldo A.M. Lima 695 Written review and editing, Lavouisier F.B. Nogueira. 696 Supervision, Alexandre Havt and Aldo A.M. Lima. 697 Project administration, Aldo A.M. Lima. 698 Resource acquisition, Aldo A.M. Lima. 699 700 Funding: This research was funded by CNPq (http://www.cnpq.br), grant numbers 701 402607/2018-0 and 408549/2022-0 and FUNCAP (https://www.funcap.ce.gov.br/), grant 702 number: OFÍCIO Nº 102/2021 – DINOV. 703 Acknowledge: This work used the following equipments (Benchtop refrigerated 704 centrifuge 10k RPM Eppendorf; Speed Vac Thermo fisher; Bead Ruptor Elite Omni 705 International Material; Thermomixer Eppendorf; Orbitrap IDX spectrometer (Thermo) 706 connected to the Vanquish UPLC system) available in the Biomolecular Analysis Core 707 Facility which is supported by the University of Virginia School of Medicine, Research

708

Resource Identifiers (RRID):SCR 025476.

709 710 Data Availability Statement: The data and reports relating to this study will be 711 available via direct request via email to the corresponding author. 712 713 Conflicts of Interest: The authors declare that there are no financial or personal 714 conflicts of interest that may have influenced the work. 715 **REFERENCES** 716 717 (1) Munita, J. M.; Arias, C. A. Mechanisms of Antibiotic Resistance. Microbiol Spectr 2016, 4 718 (2). https://doi.org/10.1128/MICROBIOLSPEC.VMBF-0016-2015. 719 (2) Frieri, M.; Kumar, K.; Boutin, A. Antibiotic Resistance. J Infect Public Health 2017, 10 (4), 720 369–378. https://doi.org/10.1016/J.JIPH.2016.08.007. 721 (3) Holt, K. E.; Wertheim, H.; Zadoks, R. N.; Baker, S.; Whitehouse, C. A.; Dance, D.; Jenney, 722 A.; Connor, T. R.; Hsu, L. Y.; Severin, J.; Brisse, S.; Cao, H.; Wilksch, J.; Gorrie, C.; Schultz, 723 M. B.; Edwards, D. J.; Van Nguyen, K.; Nguyen, T. V.; Dao, T. T.; Mensink, M.; Le Minh, 724 V.; Nhu, N. T. K.; Schultsz, C.; Kuntaman, K.; Newton, P. N.; Moore, C. E.; Strugnell, R. 725 A.; Thomson, N. R. Genomic Analysis of Diversity, Population Structure, Virulence, and 726 Antimicrobial Resistance in Klebsiella Pneumoniae, an Urgent Threat to Public Health. 727 Proc Natl Sci U S Α 2015, 112 Acad (27),E3574-E3581. 728 https://doi.org/10.1073/PNAS.1501049112/SUPPL_FILE/PNAS.1501049112.SD01.XLSX. 729 (4) Asri, N. A. M.; Ahmad, S.; Mohamud, R.; Hanafi, N. M.; Zaidi, N. F. M.; Irekeola, A. A.; 730 Shueb, R. H.; Yee, L. C.; Noor, N. M.; Mustafa, F. H.; Yean, C. Y.; Yusof, N. Y. Global 731 Prevalence of Nosocomial Multidrug-Resistant Klebsiella Pneumoniae: A Systematic 732 2021, 10 Review and Meta-Analysis. **Antibiotics** (12).733 https://doi.org/10.3390/ANTIBIOTICS10121508.

734 (5) Sharma, A.; Thakur, A.; Thakur, N.; Kumar, V.; Chauhan, A.; Bhardwaj, N. Changing 735 Trend in the Antibiotic Resistance Pattern of Klebsiella Pneumonia Isolated From 736 Endotracheal Aspirate Samples of ICU Patients of a Tertiary Care Hospital in North 737 India. Cureus 2023, 15 (3). https://doi.org/10.7759/CUREUS.36317. 738 (6) Cortés, G.; Borrell, N.; De Astorza, B.; Gómez, C.; Sauleda, J.; Albertí, S. Molecular 739 Analysis of the Contribution of the Capsular Polysaccharide and the Lipopolysaccharide 740 O Side Chain to the Virulence of Klebsiella Pneumoniae in a Murine Model of 741 Pneumonia. Infect Immun 2002, 70 (5), 2583-2590. https://doi.org/10.1128/IAI.70.5.2583-742 2590.2002/FORMAT/EPUB. 743 (7) Struve, C.; Bojer, M.; Krogfelt, K. A. Identification of a Conserved Chromosomal Region 744 Encoding Klebsiella Pneumoniae Type 1 and Type 3 Fimbriae and Assessment of the Role 745 Infect Fimbriae in Pathogenicity. Immun 2009, 77 (11),5016-5024. 746 https://doi.org/10.1128/IAI.00585-09/FORMAT/EPUB. 747 (8)Lin, C. T.; Chen, Y. C.; Jinn, T. R.; Wu, C. C.; Hong, Y. M.; Wu, W. H. Role of the CAMP-748 Dependent Carbon Catabolite Repression in Capsular Polysaccharide Biosynthesis in 749 Klebsiella Pneumoniae. PLoS2013, (2),e54430. 750 https://doi.org/10.1371/JOURNAL.PONE.0054430. 751 (9) Davies, J.; Davies, D. Origins and Evolution of Antibiotic Resistance. Microbiol Mol Biol 752 Rev 2010, 74 (3), 417. https://doi.org/10.1128/MMBR.00016-10. 753 (10)Salipante, S. J.; Jerome, K. R. Digital PCR-An Emerging Technology with Broad 754 Microbiology. 2020, 117–123. Applications in Clin Chem 66 (1),755 https://doi.org/10.1373/CLINCHEM.2019.304048. 756 (11)Fortuin, S.; Soares, N. C. The Integration of Proteomics and Metabolomics Data Paving 757 the Way for a Better Understanding of the Mechanisms Underlying Microbial Acquired

Drug Resistance. Frontiers in Medicine 2022, 9. https://doi.org/10.3389/fmed.2022.849838.

758

- 759 (12) Zeng, C.; Tandhanskul, A.; Krungkaew, S.; Likhanapaiboon, T.; Kasayapanan, W.;
- Yasurin, P.; Tang, J.; Phusantisampan, T.; Tawai, A. Research Progress on Using Omics
- 761 Technology to Examine the Antimicrobial Mechanisms of Natural Active Substances.
- 762 Applied Science and Engineering Progress 2024.
- 763 https://doi.org/10.14416/j.asep.2024.07.003.
- 764 (13) Bush, K.; Bradford, P. A. β-Lactams and β-Lactamase Inhibitors: An Overview. *Cold*
- 765 *Spring Harb Perspect Med* **2016**, 6 (8). https://doi.org/10.1101/CSHPERSPECT.A025247.
- 766 (14) Ferreira, A. M.; Martins, K. B.; Silva, V. R. da; Mondelli, A. L.; Cunha, M. de L. R. de S. da.
- 767 Correlation of Phenotypic Tests with the Presence of the BlaZ Gene for Detection of Beta-
- 768 Lactamase. *Braz J Microbiol* **2017**, 48 (1), 159–166.
- 769 https://doi.org/10.1016/J.BJM.2016.10.011.
- 770 (15) Zhu, L. J.; Pan, Y.; Gao, C. Y.; Hou, P. F. Distribution of Carbapenemases and Efflux
- Pump in Carbapenem-Resistance Acinetobacter Baumannii. *Ann Clin Lab Sci* **2020**, 50 (2).
- 772 (16) Makharita, R. R.; El-Kholy, I.; Hetta, H. F.; Abdelaziz, M. H.; Hagagy, F. I.; Ahmed, A. A.;
- 773 Algammal, A. M. Antibiogram and Genetic Characterization of Carbapenem-Resistant
- 774 Gram-Negative Pathogens Incriminated in Healthcare-Associated Infections. Infect Drug
- 775 Resist **2020**, 13, 3991–4002. https://doi.org/10.2147/IDR.S276975.
- 776 (17) Santos, A. L.; Dos Santos, A. P.; Ito, C. R. M.; de Queiroz, P. H. P.; de Almeida, J. A.;
- 777 Júnior, M. A. B. de C.; de Oliveira, C. Z.; Avelino, M. A. G.; Wastowski, I. J.; Gomes, G. P.
- 778 L. A.; E Souza, A. C. S.; Vasconcelos, L. S. N. de O. L.; Santos, M. de O.; da Silva, C. A.;
- 779 Carneiro, L. C. Profile of Enterobacteria Resistant to Beta-Lactams. Antibiotics 2020, 9 (7),
- 780 1–18. https://doi.org/10.3390/ANTIBIOTICS9070410.
- 781 (18) Abdel-Rhman, S. H. Characterization of β-Lactam Resistance in K. Pneumoniae
- 782 Associated with Ready-to-Eat Processed Meat in Egypt. PLoS One 2020, 15 (9), e0238747.
- 783 https://doi.org/10.1371/JOURNAL.PONE.0238747.

784 (19)Messaoudi, A.; Mansour, W.; Jaidane, N.; Chaouch, C.; Boujaâfar, N.; Bouallègue, O. 785 Epidemiology of Resistance and Phenotypic Characterization of Carbapenem Resistance 786 Mechanisms in Klebsiella Pneumoniae Isolates at Sahloul University Hospital-Sousse, 787 Tunisia. Afr Health Sci 2019, 19 (2), 2008–2020. https://doi.org/10.4314/AHS.V19I2.24. 788 (20) Farhadi, M.; Ahanjan, M.; Goli, H. R.; Haghshenas, M. R.; Gholami, M. High Frequency of 789 Multidrug-Resistant (MDR) Klebsiella Pneumoniae Harboring Several β-Lactamase and 790 Integron Genes Collected from Several Hospitals in the North of Iran. Annals of Clinical 791 Microbiology and Antimicrobials **2021**, 20 (1). https://doi.org/10.1186/s12941-021-00476-1. 792 (21)Oliveira, R.; Castro, J.; Silva, S.; Oliveira, H.; Saavedra, M. J.; Azevedo, N. F.; Almeida, C. 793 Exploring the Antibiotic Resistance Profile of Clinical Klebsiella Pneumoniae Isolates in 794 Portugal. Antibiotics (Basel) 2022, 11 (11). https://doi.org/10.3390/ANTIBIOTICS11111613. 795 (22)Bush, K.; Bradford, P. A. Epidemiology of β-Lactamase-Producing Pathogens. Clin 796 Microbiol Rev 2020, 33 (2). https://doi.org/10.1128/CMR.00047-19. 797 (23)Castanheira, M.; Simner, P. J.; Bradford, P. A. Extended-Spectrum β-Lactamases: An 798 Update on Their Characteristics, Epidemiology and Detection. JAC Antimicrob Resist 2021, 799 3 (3). https://doi.org/10.1093/JACAMR/DLAB092. 800 (24)Gundran, R. S.; Cardenio, P. A.; Villanueva, M. A.; Sison, F. B.; Benigno, C. C.; 801 Kreausukon, K.; Pichpol, D.; Punyapornwithaya, V. Prevalence and Distribution of 802 BlaCTX-M, BlaSHV, BlaTEM Genes in Extended- Spectrum β- Lactamase- Producing E. 803 Coli Isolates from Broiler Farms in the Philippines. BMC Vet Res 2019, 15 (1). 804 https://doi.org/10.1186/S12917-019-1975-9. 805 (25)Queiroz, J. A. da S.; Alves, L. S.; Dall'acqua, D. S. V.; Souza, L. F. B.; Faculdades 806 Integradas Aparício Carvalho. Porto Velho, R. Brasil.; Faculdades Integradas Aparício Carvalho. Porto Velho, R. Brasil.; Fundação Oswaldo Cruz. Porto Velho, R. Brasil. / F. I. 807 808 A. Carvalho, P. V. R. Brasil.; Faculdades Integradas Aparício Carvalho, Porto Velho, R.

809		Brasil. Desenho e Validação de Primers In Silico Para Detecção Do Vírus Sincicial
810		Respiratório Humano. Revista FIMCA 2017, 4 (1), 17–30.
811	(26)	Kumar, A.; Chordia, N. In Silico PCR Primer Designing and Validation. Methods Mol Biol
812		2015 , 1275, 143–151. https://doi.org/10.1007/978-1-4939-2365-6_10.
813	(27)	Rodríguez, A.; Rodríguez, M.; Córdoba, J. J.; Andrade, M. J. Design of Primers and Probes
814		for Quantitative Real-Time PCR Methods. <i>Methods in Molecular Biology</i> 2015 , 1275, 31–56.
815		https://doi.org/10.1007/978-1-4939-2365-6_3.
816	(28)	van Weezep, E.; Kooi, E. A.; van Rijn, P. A. PCR Diagnostics: In Silico Validation by an
817		Automated Tool Using Freely Available Software Programs. J Virol Methods 2019, 270,
818		106–112. https://doi.org/10.1016/J.JVIROMET.2019.05.002.
819	(29)	Yang, J.; Kemps-Mols, B.; Spruyt-Gerritse, M.; Anholts, J.; Claas, F.; Eikmans, M. The
820		Source of SYBR Green Master Mix Determines Outcome of Nucleic Acid Amplification
821		Reactions. BMC Res Notes 2016, 9 (1), 1–10. https://doi.org/10.1186/S13104-016-2093-
822		4/FIGURES/4.
823	(30)	Wang, Y.; Li, W.; Guo, X.; Zhang, D.; Sun, J.; Fu, Z.; Liu, G.; Li, Y.; Jiang, S. Development
824		of SYBR Green I-Based Polymerase Chain Reaction for Feline Bocavirus 1 Detection. 3
825		Biotech 2021, 11 (2). https://doi.org/10.1007/S13205-020-02577-8.
826	(31)	Desriani; Azamris; Ghaissani, S. S.; Kinanti, S. R.; Warisman, M. A.; Fitria, N. Design and
827		Characterization of a SYBR Green I-Based Melting Curve Method for Investigation of
828		HER2I655V Polymorphism in Breast Cancer. J Genet Eng Biotechnol 2021, 19 (1).
829		https://doi.org/10.1186/S43141-020-00108-9.
830	(32)	Svec, D.; Tichopad, A.; Novosadova, V.; Pfaffl, M. W.; Kubista, M. How Good Is a PCR
831		Efficiency Estimate: Recommendations for Precise and Robust QPCR Efficiency
832		Assessments. Biomol Detect Quantif 2015, 3, 9–16.
833		https://doi.org/10.1016/J.BDQ.2015.01.005.

834 PCR: US. (33)Thermo Fisher Scientific. Real-Time **Understanding** Ct835 https://www.thermofisher.com/us/en/home/life-science/pcr/real-time-pcr/real-time-pcr-836 learning-center/real-time-pcr-basics/real-time-pcr-understanding-ct.html (accessed 2024-837 05-05). 838 (34)Han, R.; Shi, Q.; Wu, S.; Yin, D.; Peng, M.; Dong, D.; Zheng, Y.; Guo, Y.; Zhang, R.; Hu, F. 839 Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among 840 Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in 841 China. Front Cell Infect Microbiol 2020, 10, 314. https://doi.org/10.3389/FCIMB.2020.00314. 842 (35)Marschall, J.; Tibbetts, R. J.; Dunne, W. M.; Frye, J. G.; Fraser, V. J.; Warren, D. K. Presence 843 of the KPC Carbapenemase Gene in Enterobacteriaceae Causing Bacteremia and Its Correlation with In Vitro Carbapenem Susceptibility. J Clin Microbiol 2009, 47 (1), 239. 844 845 https://doi.org/10.1128/JCM.02123-08. 846 (36)Kharazmkia, A.; Amirizadeh, M.; Goudarzi, Z.; Birjandi, M.; Barfipoursalar, A.; Mir, S. 847 Prevalence of KPC-Producing Bacteria in Negative Gram of Clinical Samples Obtained 848 from 2022, 77, 103690. Patients. Annals Medicine Surgery of and 849 https://doi.org/10.1016/J.AMSU.2022.103690. 850 (37)Pawłowska, I.; Ziółkowski, G.; Jachowicz-Matczak, E.; Stasiowski, M.; Gajda, M.; 851 Wójkowska-Mach, J. Colonization and Healthcare-Associated Infection of Carbapenem-852 Resistant Enterobacteriaceae, Data from Polish Hospital with High Incidence of 853 Carbapenem-Resistant Enterobacteriaceae, Does Active Target Screening Matter? 854 Microorganisms 2023, 11 (2). https://doi.org/10.3390/MICROORGANISMS11020437. 855 (38)Ferreira, R. L.; da Silva, B. C. M.; Rezende, G. S.; Nakamura-Silva, R.; Pitondo-Silva, A.; 856 Campanini, E. B.; Brito, M. C. A.; da Silva, E. M. L.; Freire, C. C. de M.; Cunha, A. F. da; 857 Pranchevicius, M.-C. da S. High Prevalence of Multidrug-Resistant Klebsiella 858 Pneumoniae Harboring Several Virulence and β-Lactamase Encoding Genes in a 859 Brazilian 2019, 9. Intensive Care Unit. Frontiers in Microbiology 860 https://doi.org/10.3389/fmicb.2018.03198. 861 (39)Kernéis, S.; Lucet, J. C.; Santoro, A.; Meschiari, M. Individual and Collective Impact of 862 Klebsiella Pneumoniae Carbapenemase (KPC)-Producing K. Pneumoniae in Patients 863 Admitted to the ICU. J Antimicrob Chemother 2021, 76 (Suppl 1), I19-I26. 864 https://doi.org/10.1093/JAC/DKAA494. Dirar, M. H.; Bilal, N. E.; Ibrahim, M. E.; Hamid, M. E. Prevalence of Extended-Spectrum 865 (40)β-Lactamase (ESBL) and Molecular Detection of Bla TEM, Bla SHV and Bla CTX-M 866 867 Genotypes among Enterobacteriaceae Isolates from Patients in Khartoum, Sudan. Pan Afr 868 Med J 2020, 37, 1–11. https://doi.org/10.11604/PAMJ.2020.37.213.24988. 869 (41) Pavez, M.; Troncoso, C.; Osses, I.; Salazar, R.; Illesca, V.; Reydet, P.; Rodríguez, C.; 870 Chahin, C.; Concha, C.; Barrientos, L. High Prevalence of CTX-M-1 Group in ESBL-871 Producing Enterobacteriaceae Infection in Intensive Care Units in Southern Chile. Braz J 872 Infect Dis 2019, 23 (2), 102–110. https://doi.org/10.1016/J.BJID.2019.03.002. 873 (42) Camargo, C. H.; Yamada, A. Y.; Souza, A. R. de; Reis, A. D.; Santos, M. B. N.; Assis, D. B. 874 de; Carvalho, E. de; Takagi, E. H.; Cunha, M. P. V.; Tiba-Casas, M. R. Genomic Diversity 875 of NDM-Producing Klebsiella Species from Brazil, 2013-2022. Antibiotics 2022, 11 (10), 876 1395.https://doi.org/10.3390/antibiotics11101395. 877 Vivas, R.; Dolabella, S. S.; Barbosa, A. A. T.; Jain, S. Prevalence of Klebsiella Pneumoniae 878 Carbapenemase - and New Delhi Metallo-Beta-Lactamase-Positive K. Pneumoniae in 879 Sergipe, Brazil, and Combination Therapy as a Potential Treatment Option. Revista da 880 Sociedade Brasileira de Medicina Tropical 2020, 53. https://doi.org/10.1590/0037-8682-0064-881 2020. 882 (44)Belouad, E. M.; Benaissa, E.; El Mrimar, N.; Bssaibis, F.; Maleb, A.; Elouennass, M. 883 Predominance of OXA-48 Carbapenemase-Producing Enterobacterales in a Moroccan 884 Hospital. Int J Microbiol 2023, 2023. https://doi.org/10.1155/2023/8581883.

885 (45)Magagnin, C. M.; Rozales, F. P.; Antochevis, L.; Nunes, L. S.; Martins, A. S.; Barth, A. L.; 886 Sampaio, J. M.; Zavascki, A. P. Dissemination of Bla OXA-370 Gene among Several 887 Enterobacteriaceae Species in Brazil. Eur J Clin Microbiol Infect Dis 2017, 36 (10), 1907-888 1910. https://doi.org/10.1007/S10096-017-3012-X. 889 (46)Evans, B. A.; Amyes, S. G. B. OXA β-Lactamases. Clin Microbiol Rev 2014, 27 (2), 241–263. 890 https://doi.org/10.1128/CMR.00117-13/ASSET/DF7BB1F6-F6E8-4208-8829-891 B01CD28A0242/ASSETS/GRAPHIC/ZCM9990924610006.JPEG. 892 Shahid, M.; Ahmad, N.; Saeed, N. K.; Shadab, M.; Joji, R. M.; Al-Mahmeed, A.; Bindayna, (47)893 K. M.; Tabbara, K. S.; Dar, F. K. Clinical Carbapenem-Resistant Klebsiella Pneumoniae 894 Isolates Simultaneously Harboring Bla NDM-1, Bla OXA Types and QnrS Genes from the 895 Kingdom of Bahrain: Resistance Profile and Genetic Environment. Front Cell Infect 896 Microbiol 2022, 12. https://doi.org/10.3389/FCIMB.2022.1033305. 897 (48)Manandhar, S.; Zellweger, R. M.; Maharjan, N.; Dongol, S.; Prajapati, K. G.; Thwaites, G.; 898 Basnyat, B.; Dixit, S. M.; Baker, S.; Karkey, A. A High Prevalence of Multi-Drug Resistant 899 Gram-Negative Bacilli in a Nepali Tertiary Care Hospital and Associated Widespread 900 Distribution of Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenemase-901 Encoding Genes. Clin Microbiol Antimicrob 2020, 19 (1),1–13. Ann 902 https://doi.org/10.1186/S12941-020-00390-Y/FIGURES/5. 903 (49)Awosile, B. B.; Agbaje, M.; Adebowale, O.; Kehinde, O.; Omoshaba, E. Beta-Lactamase 904 Resistance Genes in Enterobacteriaceae from Nigeria. Afr J Lab Med 2022, 11 (1). 905 https://doi.org/10.4102/AJLM.V11I1.1371. 906 (50)Han, M. L.; Nang, S. C.; Lin, Y. W.; Zhu, Y.; Yu, H. H.; Wickremasinghe, H.; Barlow, C. K.; 907 Creek, D. J.; Crawford, S.; Rao, G.; Dai, C.; Barr, J. J.; Chan, K.; Turner Schooley, R.; 908 Velkov, T.; Li, J. Comparative Metabolomics Revealed Key Pathways Associated with the 909 Synergistic Killing of Multidrug-Resistant Klebsiella Pneumoniae by a Bacteriophage910 Polymyxin Combination. Comput Struct Biotechnol 2022, 20, 485-495. 911 https://doi.org/10.1016/J.CSBJ.2021.12.039. 912 Kumar, A.; Singh, S.; Gupta, S. K.; Kumar, S.; Kumar, S.; Singh, R.; Thakur, L.; Kumar, M.; (51)913 Kapil, A.; Kumar, Y.; Kumar, N. Identification of Metabolite Extraction Method for 914 Targeted Exploration of Antimicrobial Resistance Associated Metabolites of Klebsiella 915 Pneumoniae. Sci Rep 2022, 12 (1). https://doi.org/10.1038/S41598-022-12153-0. 916 (52)Hudson, A. W.; Barnes, A. J.; Bray, A. S.; Ornelles, D. A.; Zafar, M. A. Klebsiella 917 Pneumoniae L-Fucose Metabolism Promotes Gastrointestinal Colonization 918 Modulates Its Virulence Determinants. Infect Immun 2022, 90 (10).919 https://doi.org/10.1128/IAI.00206-22. 920 (53)Lin, D.; Fan, J. M.; Wang, J.; Liu, L.; Xu, L.; Li, F.; Yang, J.; Li, B. The Fructose-Specific 921 Phosphotransferase System of Klebsiella Pneumoniae Is Regulated by Global Regulator and Linked to Virulence and Growth. Infect Immun 2018, 922 923 https://doi.org/10.1128/IAI.00340-18. 924 (54) Aminov, R. Metabolomics in Antimicrobial Drug Discovery. Expert Opinion on Drug 925 Discovery 2022, 17 (9), 1047–1059. https://doi.org/10.1080/17460441.2022.2113774. 926 (55) Kok, M.; Maton, L.; van der Peet, M.; Hankemeier, T.; van Hasselt, J. G. C. Unraveling 927 Antimicrobial Resistance Using Metabolomics. Drug Discovery Today 2022, 27 (6), 1774-928 1783. https://doi.org/10.1016/j.drudis.2022.03.015. 929 (56) Soni, V.; Wang, Z.; Singh, V. Editorial: Bacterial Metabolomics Approach towards 930 Antimicrobials Resistance. Microbiology 2023, 14. and Frontiers in 931 https://doi.org/10.3389/fmicb.2023.1222594. 932 (57) Abril, A. G.; Quintela-Baluja, M.; Villa, T. G.; Calo-Mata, P.; Barros-Velázquez, J.; Carrera, 933 M. Proteomic Characterization of Virulence Factors and Related Proteins in Enterococcus 934 Strains from Dairy and Fermented Food Products. International Journal of Molecular

Sciences 2022, 23 (18), 10971. https://doi.org/10.3390/ijms231810971.

935

It is made available under a CC-BY-ND 4.0 International license .

936	(58)	Azhar, F.; Busharat, M.; Chaudhary, S. R.; Waheed, Z.; Jamil, M. Metabolomics in Drug
937		Discovery: Restoring Antibiotic Pipeline. Asian Pacific Journal of Tropical Biomedicine 2023,
938		13 (9), 378. https://doi.org/10.4103/2221-1691.385568.
939	(59)	Tsugawa, H.; Cajka, T.; Kind, T.; Ma, Y.; Higgins, B.; Ikeda, K.; Kanazawa, M.;
940		Vandergheynst, J.; Fiehn, O.; Arita, M. MS-DIAL: Data-Independent MS/MS
941		Deconvolution for Comprehensive Metabolome Analysis. Nature Methods 2015 12:6 2015,
942		12 (6), 523–526. https://doi.org/10.1038/nmeth.3393.
943	(60)	Tsugawa, H.; Nakabayashi, R.; Mori, T.; Yamada, Y.; Takahashi, M.; Rai, A.; Sugiyama,
944		R.; Yamamoto, H.; Nakaya, T.; Yamazaki, M.; Kooke, R.; Bac-Molenaar, J. A.; Oztolan-
945		Erol, N.; Keurentjes, J. J. B.; Arita, M.; Saito, K. A Cheminformatics Approach to
946		Characterize Metabolomes in Stable-Isotope-Labeled Organisms. Nat Methods 2019, 16 (4),
947		295–298. https://doi.org/10.1038/S41592-019-0358-2.
948		